perspectiva aiqbenchAI + Cuantic

Iambic's IPO highlights a growing trend where biotech firms rely on AI-driven automated chemistry to accelerate drug discovery, with NVIDIA providing critical infrastructure support for these computational workflows. The successful pricing and entry of IAM1363 into clinical trials demonstrate the tangible commercial viability of integrating large-scale AI models into pharmaceutical R&D pipelines. This event underscores the deepening intersection between generative AI capabilities and high-value healthcare applications rather than representing a general tech market move.

Sursă care acoperă36Kr

Ce este aceastaLectura unui model asupra articolului și a acoperirii conexe, scrisă pentru aiqbench. Nu sunt cuvintele publicației.

NVIDIA-backed AI drugmaker Iambic prices IPO at $16, raising $150 million

36Kr14 octombrie 20261 min de cititArticolul și perspectiva sunt în engleză.

On October 14 local time, AI pharmaceutical company Iambic Therapeutics announced its initial public offering (IPO) pricing of $16 per share, issuing 9.375 million shares and raising an expected $150 million, with underwriters granted a 30-day option to purchase up to an additional 1.40625 million shares. The company's stock is expected to begin trading on the Nasdaq Global Select Market on October 15 under the ticker symbol 'IAM', with the offering scheduled for completion on October 16. JPMorgan, Jefferies, Bank of America Securities, and Citigroup serve as joint bookrunners. Iambic leverages artificial intelligence and automated chemistry and biology techniques to advance drug discovery, with its candidate drug IAM1363 already in clinical development. NVIDIA previously participated in supporting the company's financing. (Jiemian)

Citește articolul complet pe 36Kr

Citește pe 36Kr ↗Întreabă despre acest articol